Breast Cancer Research and Treatment
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32)
2023
-
A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in elderly breast cancer patients
2007
-
A systematic review of the role of adjuvant ovarian ablation in the treatment of women with early stage breast cancer.
2007
-
Galactose oxidase Schiff's reactivity is higher in nipple aspirate fluid from cancerous breasts than from healthy patients
2007
-
How compliant are patients with oral hormonal therapies? Data from a randomized, placebo controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (NCIC CTG MA.12)
2007
-
Long-term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node negative breast cancer
2007
-
A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCICCTG MA. 21: Results of an interim analysis
2007
-
Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33.
2006
-
Cognitive impairment associated with chemotherapy for breast cancer: A mechanistic cohort study.
2006
-
Correlation between 2 or 3 year (y) disease-free survival (DFS) and 5y overall survival (OS) in adjuvant systemic trials of early stage breast cancer.
2006
-
Evaluating the performance of risk assessment models in BRCA1 and BRCA2 mutation detection.
2006
-
The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age.
2006
-
Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5).
2006
-
Baseline radiological staging in primary breast cancer: impact of an educational intervention on adherence to published guidelines.
2005
-
Meta-analysis examining the efficacy of serotonin selective reuptake inhibitors in the treatment of women with hot flashes
2005
-
Adherence to cancer risk reduction strategies in unaffected women who attend a breast and ovarian cancer risk reduction clinic.
2004
-
Complementary and alternative medicine use among patients with locally advanced breast cancer
2004
-
Effect of letrozole versus placebo on bone mineral density in women completing >= 5 years (yrs) of adjuvant tamoxifen: ncic ctg ma.17b
2004
-
Phase II study of perifosine in metastatic or advanced breast cancer.
2004
-
HER2 status: A Canadian experience of concordance between central and local testing laboratories
2003
-
Male breast cancer: why is the incidence increasing?
2003
-
Ten-year outcome of breast-conserving surgery (BCS) and radiotherapy (RT) in women with breast cancer (BC) and germline BRCA 1/2 mutations: results from an international collaboration
2003
-
The impact of having relatives affected with breast cancer on psychological distress in women at increased risk for breast cancer (BC)
2003
-
Tissue microarrays: accurate assessment of protein and DNA targets requires 3 cores per tumor sample.
2003
-
Urgent genetic assessment (GA) in the management of newly diagnosed familial breast cancer (br ca) patients: a feasibility study
2003
-
A prospective comparison of positron emission tomography scanning, sentinel lymph node biopsy and axillary dissection in staging patients with early stage breast cancer.
2002
-
A randomized trial comparing CEF to CME in premenopausal women with node positive breast cancer: update of NCICCTG MA.5.
2002
-
Feasibility and responsiveness of utility measurement in breast cancer patients: a prospective study.
2002
-
Health related quality of life (HRQOL) and psychosocial status at diagnosis are not associated with disease-free or overall survival (DFS or OS) in T1-3, N0-1, M0 breast cancer (BC).
2002
-
NAT2 interactions on breast cancer risk: SULT1A1 and cooked meat.
2002
-
Risk of acute leukemia following adjuvant epirubicin-based adjuvant chemotherapy for breast cancer.
2001
-
Mechanisms involved in the metastasis of cancer to bone
1993
-
A RANDOMIZED TRIAL COMPARING 12 WEEKS WITH 36 WEEKS OF ADJUVANT CHEMOTHERAPY IN STAGE-II BREAST-CANCER
1988
-
HER-2/NEU ONCOGENE AS A PROGNOSTIC FACTOR IN NODE NEGATIVE BREAST-CANCER
1988
-
THE INFLUENCE OF EXOGENOUS HORMONES ON ESTROGEN AND PROGESTERONE RECEPTORS IN PRIMARY BREAST-CARCINOMA
1988
-
CANCER-CHEMOTHERAPY AND THROMBOSIS
1987
-
QUALITY-OF-LIFE IN STAGE-II BREAST-CANCER - AN INSTRUMENT FOR CLINICAL-TRIALS
1986
-
A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer.
208:523-533.
2024
-
Development and application of a weighted change score to evaluate interventions for vasomotor symptoms in patients with breast cancer using regression trees: a cohort study.
207:313-321.
2024
-
Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey.
206:473-481.
2024
-
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY..
204:237-248.
2024
-
The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey.
204:531-538.
2024
-
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.
201:257-264.
2023
-
Patient reported symptom burden amongst immigrant and Canadian long-term resident women undergoing breast cancer surgery.
199:553-563.
2023
-
Textbook outcomes in DIEP flap breast reconstruction: a Delphi study to establish consensus.
197:559-568.
2023
-
A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles.
193:1-20.
2022
-
Axillary surgery and complication rates after mastectomy and reconstruction for breast cancer: an analysis of the NSQIP database.
192:501-508.
2022
-
Comparison of upper extremity lymphedema after sentinel lymph node biopsy and axillary lymph node dissection: patient-reported outcomes in 3044 patients.
191:87-96.
2022
-
Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study.
189:797-806.
2021
-
Psychological consequences of MRI-based screening among women with strong family histories of breast cancer.
189:497-508.
2021
-
DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS.
188:133-139.
2021
-
Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers.
188:343-350.
2021
-
Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey.
187:477-486.
2021
-
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers.
187:515-523.
2021
-
Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.
187:759-768.
2021
-
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience.
184:733-741.
2020
-
Untapped "-omics": the microbial metagenome, estrobolome, and their influence on the development of breast cancer and response to treatment..
179:287-300.
2020
-
A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients.
178:327-335.
2019
-
Multiple foci of microinvasion is associated with an increased risk of invasive local recurrence in women with ductal carcinoma in situ treated with breast-conserving surgery.
178:169-176.
2019
-
Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients.
178:347-356.
2019
-
The time-varying effect of radiotherapy after breast-conserving surgery for DCIS.
178:221-230.
2019
-
Patterns of adjuvant care and outcomes of elderly women with stage I breast cancer after breast-conserving surgery: a population-based analysis.
176:657-667.
2019
-
Body mass index impacts infection rates in immediate autogenous breast reconstruction.
175:765-773.
2019
-
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
175:443-449.
2019
-
Patient-reported symptoms following mastectomy alone or lumpectomy plus radiation for early stage breast cancer: a cohort study.
175:721-731.
2019
-
Enhanced recovery after surgery (ERAS) pathways in breast reconstruction: systematic review and meta-analysis of the literature.
173:65-77.
2019
-
Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
173:455-463.
2019
-
Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study.
171:709-717.
2018
-
Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis.
170:455-476.
2018
-
Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.
170:169-177.
2018
-
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).
169:537-548.
2018
-
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213..
167:485-493.
2018
-
Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival.
172:123-132.
2018
-
Does obesity modify the relationship between physical activity and breast cancer risk?.
166:367-381.
2017
-
Ablative Therapies in Metastatic Breast Cancer: A Systematic Review.
164:13-25.
2017
-
Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32.
164:371-378.
2017
-
Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
163:631-632.
2017
-
A single-institution experience of salvage therapy for patients with early and locally advanced breast cancer who progress during neoadjuvant chemotherapy.
163:11-19.
2017
-
Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
162:1-10.
2017
-
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
161:117-134.
2017
-
A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women.
158:553-561.
2016
-
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
157:109-116.
2016
-
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
156:343-349.
2016
-
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer.
150:605-611.
2015
-
Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
149:439-448.
2015
-
Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications.
149:293-301.
2015
-
Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival.
146:583-589.
2014
-
Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancer.
146:447-450.
2014
-
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
146:421-427.
2014
-
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.
146:153-162.
2014
-
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.
144:615-624.
2014
-
Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials.
142:143-151.
2013
-
Clinical–pathologic significance of cancer stem cell marker expression in familial breast cancers.
140:195-205.
2013
-
Erratum to: Which nomogram is best for predicting non-sentinel lymph node metastasis in breast cancer patients? A meta-analysis.
139:295-300.
2013
-
Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis.
138:581-590.
2013
-
Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: a cohort study.
138:951-959.
2013
-
Which nomogram is best for predicting non-sentinel lymph node metastasis in breast cancer patients? A meta-analysis.
137:783-795.
2013
-
A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer.
136:143-151.
2012
-
Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6.
136:117-127.
2012
-
Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.
131:541-551.
2012
-
Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice.
130:49-60.
2011
-
Amplification of the prolactin receptor gene in mammary lobular neoplasia.
128:31-40.
2011
-
Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
128:401-409.
2011
-
EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.
127:831-839.
2011
-
Erratum to: Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
126:269-269.
2011
-
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.
126:215-220.
2011
-
Severe prolonged cholestatic hepatitis caused by exemestane.
121:789-791.
2010
-
Prognosis of BRCA-associated breast cancer: a summary of evidence.
119:13-24.
2010
-
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
117:183-191.
2009
-
Is red meat intake a risk factor for breast cancer among premenopausal women?.
117:1-8.
2009
-
Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial.
110:337-342.
2008
-
A Phase 2 study of perifosine in advanced or metastatic breast cancer.
108:87-92.
2008
-
Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
105:221-228.
2007
-
Dietary lignan intakes and risk of breast cancer by tumor estrogen receptor status.
99:309-311.
2006
-
The importance of temporal effects in evaluating the prognostic impact of joint ERPR expression in premenopausal women with node-positive breast cancer.
92:115-123.
2005
-
PEA3, AP-1, and a unique repetitive sequence all are involved in transcriptional regulation of the breast cancer-associated gene, mammaglobin.
89:289-296.
2005
-
Estradiol Promotes Growth and Angiogenesis in Polyoma Middle T Transgenic Mouse Mammary Tumor Explants.
78:1-6.
2003
-
Expression of Ets-related Transcription Factors and Matrix Metalloproteinase Genes in Human Breast Cancer Cells.
72:227-232.
2002
-
Body size, received dose-intensity and myelotoxicity of adjuvant chemotherapy in relation to outcome of premenopausal women with N1 breast cancer: Results from a National Cancer Institute of Canada randomized controlled trial.
69:261.
2001
-
Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter.
61:111-119.
2000
-
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.
40:171-178.
1996
-
Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer.
30:179-195.
1994
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)